Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting

Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting




Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting

LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that a poster describing the design of the Phase 1/2 trial of AU-007 will be presented during a Trials in Progress session at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. AU-007 is a monoclonal antibody computationally designed by Biolojic Design that is highly selective for the CD25-binding portion of IL-2. The ASCO meeting will take place virtually and at McCormick Place in Chicago, Illinois, from June 3-7, 2022.

Details of the Aulos poster presentation are as follows:

Title: Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors.

Abstract: TPS2671

Session Type/Title: Poster Session/Developmental Therapeutics—Immunotherapy

Session Date and Time: Sunday, June 5, 2022, 8:00 a.m.-11:00 a.m. CDT

Presenter: Jim Vasselli, M.D., Chief Medical Officer, Aulos Bioscience

About AU-007

AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by T effector cells, from binding to trimeric receptors on T regulatory cells while still allowing IL-2 to bind and expand T effector and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. AU-007 also prevents IL-2 from binding to trimeric receptors on vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

Aulos is evaluating AU-007 in an open label, first-in-human Phase 1/2 clinical trial designed to assess the safety, tolerability, immunogenicity and clinical activity of AU-007 in patients with unresectable locally advanced or metastatic cancer. To learn more about the clinical trial program, visit ClinicalTrials.gov (NCT05267626).

About Aulos

Aulos Bioscience is an immuno-oncology company working to revolutionize cancer patient care through best-in-class IL-2 therapeutics that direct patients’ immune systems toward killing tumor cells. Matching world-class machine learning from co-founder Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, is a computationally designed human antibody that harnesses the power of IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated pathway. The company was founded by Biolojic Design and ATP with $40 million in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit www.aulosbio.com.

Contacts

info@aulosbio.com
Media inquiries: Mike Beyer, Sam Brown Inc. / 312-961-2502 / mikebeyer@sambrown.com